{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:26:24Z","timestamp":1685701584500},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s12325-014-0145-5","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T08:39:33Z","timestamp":1408437573000},"page":"975-985","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Tolerability of Fixed-Combination Brinzolamide\/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine\/Timolol Fixed Combination"],"prefix":"10.1007","volume":"31","author":[{"given":"Arturo","family":"Alezzandrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Hubatsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,20]]},"reference":[{"key":"145_CR1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"145_CR2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archopht.1991.01080080050026","volume":"109","author":"A Sommer","year":"1991","unstructured":"Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090\u20135.","journal-title":"Arch Ophthalmol"},{"key":"145_CR3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00002512-200825090-00002","volume":"25","author":"CA Webers","year":"2008","unstructured":"Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008;25:729\u201359.","journal-title":"Drugs Aging"},{"key":"145_CR4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"145_CR5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jps.2600630304","volume":"63","author":"SS Chrai","year":"1974","unstructured":"Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333\u20138.","journal-title":"J Pharm Sci"},{"key":"145_CR6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","volume":"18","author":"F Djafari","year":"2009","unstructured":"Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238\u201343.","journal-title":"J Glaucoma"},{"key":"145_CR7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","volume":"5","author":"G Reardon","year":"2011","unstructured":"Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441\u201363.","journal-title":"Patient Prefer Adherence"},{"issue":"1\u20139","key":"145_CR8","first-page":"e2","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1\u20139):e2.","journal-title":"Am J Ophthalmol"},{"key":"145_CR9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350\u20135.","journal-title":"J Glaucoma"},{"key":"145_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/erp.10.83","volume":"11","author":"A Hommer","year":"2011","unstructured":"Hommer A. Role of fixed combinations in the management of open-angle glaucoma. Expert Rev Pharmacoecon Outcomes Res. 2011;11:91\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"145_CR11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2008.04.011","volume":"115","author":"M Kaback","year":"2008","unstructured":"Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%\/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115:1728\u201334.","journal-title":"Ophthalmology"},{"key":"145_CR12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/IJG.0b013e31818fb434","volume":"18","author":"G Manni","year":"2009","unstructured":"Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%\/timolol 0.5% fixed combination versus dorzolamide 2%\/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18:293\u2013300.","journal-title":"J Glaucoma"},{"key":"145_CR13","first-page":"291","volume":"5","author":"I Lanzl","year":"2011","unstructured":"Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291\u20138.","journal-title":"Clin Ophthalmol"},{"key":"145_CR14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21:337\u201348.","journal-title":"J Ocul Pharmacol Ther"},{"key":"145_CR15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/112067210801800517","volume":"18","author":"WC Stewart","year":"2008","unstructured":"Stewart WC, Kolker AE, Sharpe ED, et al. Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. Eur J Ophthalmol. 2008;18:765\u201370.","journal-title":"Eur J Ophthalmol"},{"key":"145_CR16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The Advanced Glaucoma Intervention Study (AGIS) Investigators","year":"2000","unstructured":"The Advanced Glaucoma Intervention Study (AGIS) Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"key":"145_CR17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"BC Chauhan","year":"2008","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030\u20136.","journal-title":"Arch Ophthalmol"},{"key":"145_CR18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48\u201356.","journal-title":"Arch Ophthalmol"},{"key":"145_CR19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archophthalmol.2010.196","volume":"128","author":"BC Chauhan","year":"2010","unstructured":"Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol. 2010;128:1249\u201355.","journal-title":"Arch Ophthalmol"},{"key":"145_CR20","doi-asserted-by":"crossref","first-page":"e45079","DOI":"10.1371\/journal.pone.0045079","volume":"7","author":"JW Cheng","year":"2012","unstructured":"Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7:e45079.","journal-title":"PLoS One"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0145-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T03:29:34Z","timestamp":1565753374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0145-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,20]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0145-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,20]]}}}